Funding
Series A · Biotech

Kanvas Biosciences raises $48m Series A for microbiome therapies

DCVC, Lions Capital, Gates Foundation and other participants backed the biotherapeutics company.

Updated Oct 16, 2026By RoundOS Funding desk

Kanvas Biosciences raised $48 million in Series A financing on May 6. Named participants included DCVC, Lions Capital, Gates Foundation, ATHOS, Germin8, Ki Tua Fund, Pangaea Ventures, Alumni Ventures, Boutique Venture Partners and other backers.

The company develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy.

Funding history

Series A · This round$48M

Sources

  1. Kanvas Biosciencesprojectstartups.com
  2. businesswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Knowledge Work

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.

¥4.8BSeries C debt second close · Oct 23, 2026

Related